Ractigen’s RAG-17 Shows Early Promise in ALS — Strong Biomarker Signals From Phase I

In neurodegenerative diseases, early data is usually incremental. This one isn’t. Ractigen Therapeutics just reported Phase I data for its siRNA candidate RAG-17, and the signals are hard to ignore.

The Setup: Targeting a Defined Genetic Subset of ALS

RAG-17 is being developed for:

• Amyotrophic Lateral Sclerosis (ALS)
• Specifically, patients with SOD1 gene mutations

Why this matters:

• SOD1-ALS has a clear biological target
• But still lacks effective disease-modifying therapies

That combination, clear target, unmet need—is where breakthroughs tend to happen.

Where the Data Was Presented

The results were unveiled at the American Academy of Neurology Annual Meeting on April 19, 2026. Presented by Zhi-Ying Wu, the data covers the single ascending dose (SAD) portion of an ongoing Phase I/II trial.

The Headline Results: Biomarkers Moved—A Lot

Here’s what stands out from the blinded Phase I data:

1. Strong Safety Profile

• No serious adverse events (SAEs)
• No Grade 3 treatment-related events
• Only three mild adverse events reported

For a CNS-targeting therapy, that’s a clean start.

2. Clear Target Engagement (SOD1 Reduction)

• 58.1% reduction in CSF SOD1 protein (150 mg cohort)
• Effect sustained through Day 210

This confirms the drug is doing what it’s designed to do: silence the disease-driving gene.

3. Deep Neurodegeneration Signal (NfL Reduction)

• 81.2% reduction in plasma neurofilament light chain (NfL) (180 mg cohort)

NfL is a key marker of neuronal damage. A drop this large is rare, especially after a single dose.

4. Early Clinical Stabilization Signals

• At Day 90: no functional decline in evaluated patients
• At Day 150: only minimal decline (0–4 ALSFRS-R points)

Small sample, early data—but directionally important.

The Technology: Why RAG-17 Is Different

RAG-17 uses:

• siRNA (small interfering RNA) to silence SOD1
• Delivered via Ractigen’s SCAD™ platform

Key innovation:

• Conjugation to an accessory oligonucleotide (ACO)
• Enables:
  • Broad CNS distribution
  • Durable activity after a single intrathecal dose

Translation: Fewer injections, longer effect, better patient experience.

Leadership Perspective: “Unprecedented” Signal

Long-Cheng Li called out two standout points:

• 81% NfL reduction
• Strong safety from a single administration

His framing is bold: Potentially unprecedented signal in this patient population. That’s a big claim, but the data gives it some weight.

Phase II Already Underway

Ractigen isn’t waiting. A Phase II trial is now in progress:

• Multiple ascending dose (MAD) design
• Evaluating:
  • Safety
  • Pharmacokinetics (PK)
  • Pharmacodynamics (PD)
  • Early efficacy

Sites span major institutions across China, including:

• Beijing Tiantan Hospital
• West China Hospital of Sichuan University

Enrollment for initial cohorts is already complete.

Regulatory Tailwinds

RAG-17 has secured:

• Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration
• Inclusion in the CARE program by China’s National Medical Products Administration

These programs are designed to accelerate rare disease therapies.

Reality Check: What to Watch Next

Before getting carried away, a few constraints:

• Small sample size (early phase)
• Blinded data
• Biomarkers ≠ clinical outcomes (yet)

The key questions going forward:

• Do these biomarker gains translate into meaningful clinical benefit?
• Can durability hold with repeat dosing?
• Does safety remain clean at scale?

Final Take

RAG-17 checks three critical early boxes:

• Target engagement
• Biomarker impact
• Initial safety

That’s rare in ALS. But the real test starts now. If Phase II confirms even part of this signal,
this program moves from interesting to serious contender, fast.